#Japan #Tokyo #Precision Oncology #SOPHiA GENETICS #ADAM Innovations

A.D.A.M. Innovations Partners with SOPHiA GENETICS to Revolutionize Liquid Biopsy Testing in Japan

In a groundbreaking announcement at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, A.D.A.M. Innovations, a prominent private genetic testing firm in Japan, has partnered with SOPHiA GENETICS, an innovative AI technology company, to introduce advanced liquid biopsy tests tailored for precision oncology in Japan. This collaboration marks a significant leap forward in the realm of personalized cancer care, emphasizing the importance of timely and accurate diagnostics.

The Partnership in Detail

This strategic alliance aims to integrate cutting-edge genomic diagnostics through liquid biopsy testing, which allows for the detection of cancer-related genome changes from a single blood sample. A.D.A.M. Innovations, with its state-of-the-art laboratory situated in the heart of Tokyo, has a rich history of over 20 years in providing genetic testing services, having conducted more than 2.8 million tests. By leveraging the power of the SOPHiA DDM™ platform, which analyzes complex genomic data using AI, A.D.A.M. Innovations is set to elevate its testing capabilities to new heights.

The initial focus of the collaboration is the launch of the MSK-ACCESS® application, an innovative liquid biopsy test designed to detect circulating tumor DNA (ctDNA). With this minimally invasive approach, the goal is to improve the accuracy of diagnostics, significantly reducing false positives while ensuring rapid turnaround times for test results.

Enhancing Patient Care

One of the primary benefits of this partnership is the ability to perform tests locally and analyze samples internally. This strategic move is expected to lower costs for patients while fostering local cancer research initiatives. Furthermore, A.D.A.M. Innovations aims to expand its service offering by developing a companion diagnostic (CDx) for liquid biopsy tests. This advancement is crucial, as it is projected to facilitate broader access to high-quality tumor profiling tests for patients across Japan, enabling more tailored health care solutions.

Testing is not just about results; it's about improving the patient journey. Ross Muken, the president of SOPHiA GENETICS, emphasized the importance of making precision oncology more accessible to patients in Japan. By combining A.D.A.M. Innovations' extensive clinical expertise with the global outreach of the SOPHiA DDM™ platform, both companies are set to accelerate the implementation of data-driven medicine, which will ultimately advance both clinical research and the provision of personalized cancer care.

The Future of oncological practices in Japan

Michel Mommejat, President of A.D.A.M. Innovations, noted that the partnership represents a significant step forward in accelerating precision oncology throughout Japan. By facilitating local testing, turnaround times are expected to improve, costs will decrease, and patient care will see enhancements all around.

This collaboration is not just a business deal; it is a commitment to a vision where cutting-edge technology and patient-centered care converge. By integrating advanced liquid biopsy solutions into the healthcare landscape, A.D.A.M. Innovations and SOPHiA GENETICS are poised to make a lasting impact on cancer diagnostics and treatment modalities in Japan.

As this partnership unfolds, it will undoubtedly attract attention within the pharmaceutical sector, providing new opportunities to speed up drug development and enhance market access in Japan through the introduction of innovative diagnostic tools.

For further information, interested parties are encouraged to visit the SOPHiA GENETICS and A.D.A.M. Innovations booths at ESMO, located at stand #2039 from October 17th to 21st, 2025.

For more insights on SOPHiA GENETICS, visit SOPHiAGENETICS.COM or connect on LinkedIn. For details on A.D.A.M. Innovations, check ADAM-INNOVATIONS.COM or reach out via LinkedIn.